Our Mission
"Putting together the brightest minds involved in basic science, drug development, veterinary medical practice and commercialization to develop new cures through the most rapid means possible."
|
Zander Therapeutics, Inc. is a veterinary biotechnology company that is a subsidiary of Entest Group Inc. (a publicly traded company -- OTCPINK: ETNI). Zander is focused on developing veterinary treatments for cancer and autoimmune disorders (such as arthritis). We are targeting canine cancer, especially considering that 50% of all dogs over the age of 10 years will develop some form of cancer. Feline Leukemia (FL) is another focal point, with 2-3% of all cats in the United States carrying the feline leukemia virus. Additionally, we are looking at arthritis in animals from dogs and cats to thoroughbred horses.
Our goal is to utilize small molecule therapies for treating autoimmune disorders (arthritis) in animal companions, feline leukemia (cats) and canine cancer (dogs). Currently, Zander Therapeutics is developing products treating blood disorders using small molecules based on nuclear receptor NR2F6 under an exclusive license agreement for veterinary use from Regen BioPharma Inc. (OTCQB: RGBP). |
|
Ongoing objectives include gene silencing for treating cancer with immunotherapy, modulating key molecular processes in cancer stem cells through Zander’s patented molecular targeting approaches and repairing damaged bone marrow in animals with aplastic anemia and bone marrow suppression due to side effects of chemotherapy/radiotherapy-treated cancer patients.
ProductsZander Therapeutics' main areas of interest include: autoimmune disorders such as arthritis, immunotherapies for cancer treatment in canines and bone marrow suppression therapy for animals treated with chemotherapy and radiation therapy.
Complete listing, click "READ MORE". |
InvestorsTrack our parent company stock performance and news feed and access other important investment information.
|
NewsRead about Zander Therapeutics’ latest news releases, media coverage and company developments.
|